The companies believe that by combining their respective strengths they will be better equipped to compete and serve clients in the market for commercialisation and medical science liaison (MSL) services.
PDI’s commercialisation business has struggled in recent quarters, during which the company canceled its unprofitable contract with Novartis, and became the focus of an operational review.
This review may have led to the alliance with TMAC and could mean PDI is again pursuing contracts for its commercialisation sector, which it said it had stopped actively doing In March.
Nancy Lurker, CEO of PDI, said: “The MSL plays an increasingly crucial role in pharmaceuticals today – that of providing high-level scientific information to key opinion leaders and other medical doctors on a peer-to-peer basis.
“We’re very pleased to partner with TMAC through this strategic alliance. TMAC’s expertise in providing MSL services to pharmaceutical companies is highly regarded. Our agreement increases PDI’s ability to provide maximum value to our clients and fills a critical need for a higher science personal engagement with physicians.”
MSL from TMAC
TMAC is a specialist in providing MSL teams, which it believes are uniquely placed to communicate information about new approaches to disease management and new or expanded product ranges.
This is achieved by putting all MSLs TMAC recruits through its in-house training, which is designed to equip staff with the skills, scientific proficiency and credibility needed to communicate effectively with physicians.